Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study

Medullary carcinoma (MC) is a rare tumor with solid growth pattern without glandular differentiation and constitute less than 1% of colorectal cancer. Lymph node positivity and distant organ metastasis were reported to be lower than other poorly differentiated adenocarcinomas. Therefore, the diagnosis of MC is pathologically important in terms of follow-up and treatment. MC is commonly localized in the right colon, has a large tumor size, and is mostly diagnosed in the T4 stage. As MC most likely have defects in DNA MMR, the correct pathological diagnosis is important for the postoperative treatment and the prognosis of the patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Medullary Carcinoma Adenocarcinoma Carcinoma Carcinoma, Medullary Carcinoma, Neuroendocrine Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Genomic Instability Intestinal Diseases Intestinal Neoplasms Microsatellite Instability Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Pathologic Processes Pathological Conditions, Signs and Symptoms Rectal Diseases

Sex eligibility

All sexes

Study type

Observational

About this study

427 patients with colorectal cancer who were underwent surgery between January 2011 and December 2017, were evaluated retrospectively into 2 groups as MC (n:13) and non-MC (n:414) in terms of demographic characteristics, pathological data and oncological outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

colorectal cancer diagnosis, medullary carcinoma

Exclusion criteria

none

Treatment and study plan

Primary outcomes

Overall survival of medullar colorectal carcinomas

Time frame: 7 years

Sponsors and collaborators

Lead sponsor

V.K.V. American Hospital, Istanbul

Other

Registry information

Important dates

Study start: 2011
Primary completion: 2017
Study completion: 2018
First posted: Dec 13, 2018
Registry last updated: Dec 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed